Please login to the form below

Not currently logged in

New US pharma firm debuts

New American Therapeutics has been launched in the US, with a focus on building a pharmaceutical presence around selected physician specialties

Two veteran pharmaceutical executives have teamed up to launch a company known as New American Therapeutics, which will focus on establishing a pharmaceutical presence built around selected physician specialties.

The company has been founded by Timothy Rothwell, former chairman, CEO and president of sanofi-aventis (S-A) US, and Alan Rubino, a former executive at Hoffmann-La Roche who also served as CEO of two emerging pharmaceutical companies. Rubino will serve as CEO and president of the new company, and Rothwell will serve as chairman. 

The Cranford, New Jersey-based company is funded through a partnership with the privately owned healthcare investment management firm Deerfield Management Company.

In its first major business move, New American Therapeutics recently acquired all US rights to manufacture and market the topical antiviral drug Denavir (penciclovir cream), which has been sold by Novartis as a treatment for cold sores for nearly 15 years.

New American Therapeutics said it plans to boost marketing support for the drug, which currently has about a 50 per cent prescription share of the topical antiviral market and brings in about $100m annually "despite not receiving an adequate marketing investment."

The company said that Denavir's established revenue stream will provide the capital necessary to grow its infrastructure as well as to acquire other marketed products that could benefit from its commercialisation model.

Rothwell was chairman of S-A US from February 2007 to March 2009 and was president and CEO of the company from September 2004 to February 2007. Earlier in his career, he served as president and chief executive officer of Sanofi-Sythelabo, and as CEO of Sandoz Pharmaceuticals.

Rubino was most recently CEO and president of Akrimax Pharmaceuticals. Prior to Akrimax, he was president and chief operating officer of Pharmos Corporation. Other key executives at the new company include chief financial officer Bryan Sendrowski and Carl Sailer, vice president of commercial operations, both of whom previously had the same titles at Akrimax.

28th October 2010


Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...